Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
ACCESS-Leukemia: Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1\. Adult patients ≥18 years who are newly referred to the outpatient Adult Leukemia Treatment Program with the following diagnoses: 1. Acute myeloid leukemia (AML) 2. Acute lymphoblastic leukemia (ALL) 3. Intermediate or high-risk myelodysplastic syndrome (MDS), as defined by the revised International Prognostic Scoring System (IPSS-R) and/or IPSS-molecular (IPSS-M) 4. Intermediate or high-risk chronic myelomonocytic leukemia (CMML) by the CMML-specific prognostic scoring system (CPSS-Mol) 5. Patients with lower risk MDS or CMML may also be included if baseline peripheral blood labs indicate anticipated transfusion dependence, defined as needing ≥2 units of red blood cells every 28 days 6. Patients with lower risk MDS or CMML may also be included if anticipated visits with the leukemia clinic exceed once per month by primary oncologist 2\. Ability to complete surveys in English, Spanish, or with assistance of an interpreter. Exclusion Criteria: 1. Adults unable to consent due to lack of capacity based on their leukemia clinician assessment. 2. Individuals who are not yet adults (infants, children, teenagers).
About the study
The purpose of this study is to explore if screening health-related social needs and early social work consultation is feasible and acceptable for adults with leukemias. The study examines whether the intervention (ACCESS-Leukemia) improves outcomes. Researchers will compare social determinants of health screening and early involvement of social work to usual care.
What is being tested
- ACCESS-Leukemia (behavioral)
Sponsor: Massachusetts General Hospital · Participants: 80 · Started: Jul 14, 2026
Contact the study team
- Michelle H Lee, MD · Phone: 617-882-6060
Official record on ClinicalTrials.gov — NCT07671209
Locations in the U.S.
| Massachusetts | Mass General Brigham Cancer Institute, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.